Zapping depression Philadelphia Inquirer, PA - No incidents were reported in data on 10000 sessions submitted to the FDA. Neuronetics didn't seek approval to treat all major depression; ...
Drug Trial Publication Bias and the FDA ScienceBlogs - 34 minutes ago Finally, nine out of 99 conclusions differed between the NDAs and the papers; each time, the published conclusion favored the test drug. ...
Source: Google News
Recent News and Articles on the Keywords: times + drug + morphine Related to the article below (Last Update: 8/5/2008)
Fentanyl found in bust Weatherford Democrat, TX - Fowler said dealers are offering the drug as hospital-grade morphine, when it is actually 80 times more potent. ?They are peddling it out there as morphine...
My brain on drugs PR CannaZine (press release), UK - Aug 4, 2008 Morphine must really be a pain killer drug and if no pain, no affect. Stupid, I know, to experiment with this but experiment and perhaps closer to my Dad. ...
The Shaman?s Pharmacy UMass Magazine Online, MA - While it?s true that common drugs are derived from plants?such as the opiate morphine, made from poppies?our current drug laws do not allow medicinal plants ...
'Your whole world is turned upside down' Galena Gazette, IL - Now he's frequently on morphine, oxycontin, opiates and an anti-anxiety drug, which make him forgetful and leave him too disoriented to drive. ...
Nurse jailed for raping female patient NEWS.com.au, Australia - Jul 27, 2008 The court was told Carroll did so, but returned later with a second injection, this time containing morphine. Ms Wooldridge told the court Carroll injected ...
Drug-related deaths hit new high in Utah Salt Lake Tribune, United States - Jul 30, 2008 Oxycodone, morphine and methadone were found in more victims than any other drugs, according to the medical examiner's data. It does not indicate whether ...
Evidence from rats that morphine tolerance is a learned response. S Siegel - J Comp Physiol Psychol, 1975 - ncbi.nlm.nih.gov ... of morphine if tolerance is to be observed, (b) a hyperalgesic conditioned response
may be observed in morphine-tolerant subjects when drug administration cues ...
Evaluation of the discriminative effects of morphine in the rat. HE Shannon, SG Holtzman - J Pharmacol Exp Ther, 1976 - ncbi.nlm.nih.gov ... by morphine were further characterized by evaluating the capacity of prototypes
of other classes of psychoactive drugs to produce morphine-like discriminative ...
THE EVALUATION OF THE ANALGESIC ACTION OF PETHIDINE HYDROCHLORIDE (DEMEROL) G WOOLFE, AD MACDONALD - Journal of Pharmacology and Experimental Therapeutics, 1944 - ASPET ... that the drug had a marked analgesic effect in dogs ... found it to be five to ten times
as effective ... pethidine with codeine and morphine on human subjects, using ... -
FDA approves synthetic drug 1,000 times stronger than morphine
WASHINGTON — A synthetic form of a sea-snail venom was approved yesterday by the Food and Drug Administration as a novel approach to treating severe, chronic pain.
The drug, called Prialt, was approved for hard-to-treat pain associated with cancer, AIDS and neuropathies. Based on a compound found in the poison of the South Pacific cone snail, it controls pain in an entirely new way — by blocking the calcium channels in nerve cells that transmit pain signals — and may have broad implications for pain management.
Because it is as much as 1,000 times more powerful than morphine, it is considered a last resort for long-suffering patients, rather than a first-line pain medication.
"This drug is very exciting because it's a very potent analgesic but isn't a narcotic," said Richard Rauck, of Wake Forest University Medical Center and the Carolinas Pain Institute. Rauck, an investigator for one of the clinical trials that led to yesterday's FDA approval, said he found the drug to be "effective in almost all types of chronic pain it's been studied in."
What will limit the use of Prialt is that it cannot be taken in pill form. It must be delivered directly into the fluid surrounding the spinal cord, which carries it to the brain without affecting other organs. Because it is so potent, tiny amounts of the drug could be dangerous to the heart and possibly other organs.
This drug is for patients in chronic and severe pain who are not getting substantial and meaningful relief with oral opiates or are having unacceptable side effects with them," said Robert Meyer, director of the FDA's Office of Drug Evaluation II.
Nonetheless, Lars Ekman, president of Élan Inc. of Ireland, the drug's maker, said up to 100,000 people in the United States might be helped by the drug.
About 50,000 patients already use devices that pump morphine directly into the spinal column, he said, and many of them may want to try Prialt because opioids can gradually lose their effectiveness. In addition, many patients in severe pain who take pain pills may want to try the spinal-cord route if the drug involved is not an opioid, he said.
"There are thousands of people out there who have pain like a bad toothache all day and night, week after week," Ekman said. "Many of these people have tried morphine, and it either didn't work or made them unable to function."
Prialt is a synthetic form of the venom that the Conus magus snail, which lives in tropical saltwater shallows, uses to stun passing prey.
Prialt, expected to reach the market next month, will come with a "black box" warning — the FDA's strongest warning — regarding its risks, which include hallucinations and even psychosis.
Despite Prialt's limitations, Mary Pat Aardrup, executive director of the National Pain Foundation, a nonprofit education group, called it a "red-letter day" for pain patients. "To have another pain drug in an entirely new class is very exciting and very hopeful."